Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 1

Conditions

COVID-19 2Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cisplatin 3202Cyclophosphamide 3195Carboplatin 2977Radiotherapy 2790Paclitaxel 2718Gemcitabine 2572pembrolizumab 2385Bevacizumab 2209Docetaxel 2199Fluorouracil 1851Capecitabine 1833Oxaliplatin 1742Dexamethasone 1605Nivolumab 1581Doxorubicin 1501Rituximab 1488Magnetic Resonance Spectroscopy 1387Etoposide 1346Irinotecan 1248Leucovorin 1226Drug Therapy 1205Cytarabine 1130Pemetrexed 1076fludarabine 1063Specimen Handling 1017Vincristine 964Cetuximab 945Trastuzumab 945Prednisone 942Lenalidomide 937

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
cilgavimab and tixagevimab drug combination × Clear all
NCT05465876 2024-04-04

PACE-CLL

Sunnybrook Health Sciences Centre

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

COVID-19, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05438498 2023-09-08

Real World Evaluation of the Effectiveness of AZD7442 for Prevention of SARS-CoV-2

MediMergent, LLC

Phase 3 Terminated
550 enrolled
Other hematologic neoplasm

COVID-19, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡